Gamma-aminobutyric acid type A receptor subunit alpha 6 (GABRA6) (GABRA6)

The Gamma-aminobutyric acid type A (GABA-A) receptor alpha6-containing subtype is a pentameric ligand-gated ion channel primarily localized in the cerebellar granule cells and the trigeminal ganglia (UniProt P47870). It is distinguished from other GABA-A subtypes by its unique pharmacology, specifically its insensitivity to classical benzodiazepines like diazepam and its high sensitivity to the antagonist furosemide (Sieghart & Savic, 2018). Biologically, it predominantly mediates tonic inhibition, providing a persistent inhibitory baseline that regulates neuronal excitability and filters sensory signal processing (Fan et al., 2018). This receptor has gained significant interest as a therapeutic target for orofacial pain, migraine, and essential tremor due to its highly restricted expression pattern, which minimizes the risk of sedative or cognitive side effects associated with broader GABAergic modulation (Chiou et al., 2011). Recent drug development efforts have focused on selective positive allosteric modulators (PAMs) like DK-I-56-1 to enhance its inhibitory function for treating chronic pain and neuropsychiatric disorders (Nutsch et al., 2022).

Other names

GABA(A) receptor subunit alpha-6Alpha-6 GABA-A receptorGABR A6GABA-A receptor alpha-6 subunit

Positive allosteric modulation (PAM) of GABA-induced chloride currents or selective antagonism of the ion channel pore.